
Kalustyan's In Manhattan: International Spice Store And Now Packaged Goods
If customers are looking for Mediterranean oils, Japanese condiments, African grains, Latin American sauces or European delicacies, they can find them at Kalustyan's spice store located on Lexington Avenue and 28th Street in Manhattan's Curry Hill or Little India district, explains Ashfer Biju, a chef working with the brand on developing new products.
Kalustyan's is arguably the largest international spice shop located in New York City, and it's branching out into a new revenue stream.
It started producing a separate consumer packaged goods line of Indian curry, simmer sauces and soon chutneys, including its popular tikka masala sauce. Its owners Aziz Osmani and Syedul Alam developed these CPGs (consumer-packaged goods) when the pandemic curtailed their retail business. Its products are sold in 55 Whole Foods stores in the Northeast, select stores in NYC's five boroughs, and nationally on Amazon.com and via mail order.
Change Is Constant
The name of the game at Kalustyan's is change. It opened in 1944, as a 1,000 square foot spice store that specialized in Armenian products including dried fruits, nuts, oils and grains. Its original owner Kerope Kalustyan, was an Armenian from Turkey when the surrounding neighborhood was mostly Armenian. Osmani and Alam took ownership in 1980.
Keeps Expanding
Since then, it has taken over two store fronts, and now measures 6,500 square feet with a 3,000 square foot basement, or 6 times its original size. Now it specializes in South Asian goods and sells items from 80 countries, Biju points out.
Variety Rules
What makes it special, says co-owner Osman, is 'the variety of ingredients in every category including its salt section, covering hundreds of salts from many countries; food additives, botanicals, like dried edible flowers, bitter syrups for cocktails and dried chiles for cooking, and spice blends.'
Many of them are sourced domestically but it also imports spices from 18 different counties. And it has Nigel on staff who sources new items that customers request that it doesn't carry and writes the detailed labels on each new product, which professional and amateur chefs scrutinize.
Biju says its target audience is varied including 'home cooks, chefs, and food lovers seeking authentic ingredients from around the world.'
Now its neighborhood is called Little India because of the many Indian eateries in its vicinity. But Kalustyan's products are international in scope cutting across many South Asian cultures.
The bulk of its revenue stems from sales at its retail shop, and its consumer package goods business is just gaining momentum. Next in line of supermarket goods is a range of chutneys including its special house recipe mango chutney.
Osmani says the new line of products sold at supermarkets 'wants to use the Kalustyan's reputation, and we thought there was a gap in the marketplace for authentic, ready to eat food that we could bring to the industry.' They're manufactured in Lancaster, Pa.
It presented its CPG products at the Fancy Food Show in late June at the Javits Center in NYC. Its goal was to 'get the name out there, for people to get to know our products, and open up some new doors,' Osmani notes.
He says he expects revenue to grow from the product line as its innovates new products and extends its supermarket to more of a national presence from the Northeast. Its simmer sauces, for example, he notes can be used on top of pastas, tofu, vegetables such as sauteed butternut squash, and cheeses.
Granted a tour by Ashfer Biju of what Kalustayan's carries, it's a veritable panoply of Middle Eastern and global spices. Chile spices from Peru, for example, warrants its own section (Who knew there were so many?). You need kashamiri red chile powder; this is the place for you. And black teas of many styles are available.
Kalustayan's makes its own baklava in the back kitchen and its feta cheese, but no longer has the room to makes prepared dinners the way it used to.
Osmani summarizes Kalustayan's as 'a destination store for people who come from all over the world including celebrated chefs and amateur chefs, people who attend culinary school, to food distributors, food writers and food critics, all of whom like to explore new items.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
What Makes Eli Lilly and Company (LLY) a Lucrative Investment?
Baron Funds, an investment management company, released its 'Baron Health Care Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care Index (benchmark) and a 10.99% gain for the Russell 3000 Index (the Index). In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Eli Lilly and Company (NYSE:LLY). Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company headquartered in Indianapolis, Indiana. The one-month return of Eli Lilly and Company (NYSE:LLY) was -2.64%, and its shares lost 5.52% of their value over the last 52 weeks. On July 30, 2025, Eli Lilly and Company (NYSE:LLY) stock closed at $760.08 per share, with a market capitalization of $682.351 billion. Baron Health Care Fund stated the following regarding Eli Lilly and Company (NYSE:LLY) in its second quarter 2025 investor letter: "We added to our position in Eli Lilly and Company (NYSE:LLY), a global pharmaceutical company best known for developing and selling GLP-1 medications for diabetes and obesity. The most recent generation of GLP-1 drugs (brand names Mounjaro and Zepbound) not only offer superb blood sugar control for diabetics, but also can drive 20% or greater weight loss and likely improve cardiovascular outcomes in both diabetic and non-diabetic obese patients. We think these drugs will become the standard of care for both diabetes and obesity, and will become a $150 billion category. We see Lilly as the leader in the space, setting a high efficacy bar with their GLP-1s on the market and continuing to innovate and develop next-generation medications that are more effective and more convenient. We are excited about once-daily oral orforglipron, which recently showed Phase 3 data in type 2 diabetes that rivaled Novo Nordisk's injectable Ozempic. We expect Phase 3 orforglipron in obesity this summer to also be competitive with Novo Nordisk's injectable Wegovy. Beyond orforglipron, Lilly is also studying a high efficacy injectable (retatrutide) in Phase 3, an amylin hormone analogue (eloralintide) that can be combined with Zepbound in Phase 2, and a muscle preserving drug bimagrumab (which can also be combined with Zepbound) in Phase 2. We continue to think this market is in the early innings of uptake, we think the adoption of GLP-1s will drive Lilly to triple its total revenues by 2030, and we think Lilly has the pipeline portfolio of drugs to sustain its leadership position." Eli Lilly and Company (NYSE:LLY) is in 21st position on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 119 hedge fund portfolios held Eli Lilly and Company (NYSE:LLY) at the end of the first quarter, which was 115 in the previous quarter. Eli Lilly and Company (NYSE:LLY) reported strong results in first quarter of 2025, with revenue increasing 45% compared to Q1 2024. While we acknowledge the potential of Eli Lilly and Company (NYSE:LLY) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Eli Lilly and Company (NYSE:LLY) and shared the list of stocks Jim Cramer recently discussed. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Excellent Execution Drove IDEXX Laboratories (IDXX) Shares Amid Macro Challenges
Baron Funds, an investment management company, released its 'Baron Health Care Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care Index (benchmark) and a 10.99% gain for the Russell 3000 Index (the Index). In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as IDEXX Laboratories, Inc. (NASDAQ:IDXX). IDEXX Laboratories, Inc. (NASDAQ:IDXX) develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets. The one-month return of IDEXX Laboratories, Inc. (NASDAQ:IDXX) was 4.58%, and its shares gained 22.08% of their value over the last 52 weeks. On July 30, 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) stock closed at $572.09 per share, with a market capitalization of $46.009 billion. Baron Health Care Fund stated the following regarding IDEXX Laboratories, Inc. (NASDAQ:IDXX) in its second quarter 2025 investor letter: "Shares of veterinary diagnostics leader IDEXX Laboratories, Inc. (NASDAQ:IDXX) contributed to performance for the quarter after reporting better than-expected financial results. Foot traffic to veterinary clinics in the U.S. remains under pressure, which has continued to hamper aggregate revenue growth. Despite macroeconomic challenges, IDEXX's excellent execution has enabled the company to maintain strong performance. We believe competitive trends are outstanding, and we expect new proprietary innovations and field sales force expansion to be meaningful contributors to growth in 2025. We see increasing evidence that long-term secular trends around pet ownership and pet care spending have structurally accelerated, which should help support IDEXX's long-term growth rate." A veterinarian in a veterinary clinic examining a companion animal. IDEXX Laboratories, Inc. (NASDAQ:IDXX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 51 hedge fund portfolios held IDEXX Laboratories, Inc. (NASDAQ:IDXX) at the end of the first quarter, which was 58 in the previous quarter. In the first quarter of 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) reported organic revenue growth of 5% driven by 4.5% organic revenue gains in the CAG business, 7% organic growth in water, and 4% organic growth in LPD. While we acknowledge the potential of IDEXX Laboratories, Inc. (NASDAQ:IDXX) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered IDEXX Laboratories, Inc. (NASDAQ:IDXX) and shared the list of best stocks to buy according to Brasada Capital Management. In Q2 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) contributed to Conestoga Capital Advisors' performance. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Baron Health Care Fund Reacquired Edwards Lifesciences Corporation (EW) in Q2. Here's Why
Baron Funds, an investment management company, released its 'Baron Health Care Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care Index (benchmark) and a 10.99% gain for the Russell 3000 Index (the Index). In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Edwards Lifesciences Corporation (NYSE:EW). Edwards Lifesciences Corporation (NYSE:EW) offers products and technologies for structural heart disease and critical care monitoring. The one-month return of Edwards Lifesciences Corporation (NYSE:EW) was 5.69%, and its shares gained 31.20% of their value over the last 52 weeks. On July 30, 2025, Edwards Lifesciences Corporation (NYSE:EW) stock closed at $81.16 per share, with a market capitalization of $47.608 billion. Baron Health Care Fund stated the following regarding Edwards Lifesciences Corporation (NYSE:EW) in its second quarter 2025 investor letter: "We reacquired shares of Edwards Lifesciences Corporation (NYSE:EW), a leading manufacturer of heart valve replacement and repair products. Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure to treat aortic stenosis, a disease that obstructs the flow of blood out of the aortic valve, which strains the heart. Edwards Lifesciences has a leading position in the TAVR market backed by a robust body of clinical evidence and physician familiarity with the product and workflow. TAVR is a $5 billion market that still continues to grow many years after Edwards Lifesciences first entered the market. We expect this growth to continue at a moderate pace as indications expand to cover a broader patient population. In addition, competitor Boston Scientific Corporation recently exited the TAVR market, which provides incremental market share opportunity for Edwards Lifesciences. A skilled surgeon surrounded by a team of medical professionals performing a Transcatheter Heart Valve Replacement. Edwards Lifesciences Corporation (NYSE:EW) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 63 hedge fund portfolios held Edwards Lifesciences Corporation (NYSE:EW) at the end of the first quarter, which was 67 in the previous quarter. Edwards Lifesciences Corporation (NYSE: EW) reported total sales of $1.53 billion in Q2 2025, reflecting a growth of 10.6%, which exceeded expectations. While we acknowledge the potential of Edwards Lifesciences Corporation (NYSE:EW) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we discussed Edwards Lifesciences Corporation (NYSE:EW) and shared Jim Cramer's latest thoughts. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.